Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,764 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 2 Clear all
Completed Phase 3 Interventional

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT00279045
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, glyburide, metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
4,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
178
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

NCT00380445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 65 Years
Enrollment
21 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and metformin, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus

NCT01241253
View directory record Official record
Conditions
Blood Glucose, Type 2 Diabetes Mellitus
Interventions
Whole cooked beans with rice meals
Other
Lead sponsor
Arizona State University
Other
Eligibility
35 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 13, 2026, 5:51 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

NCT07502495
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
icovamenib 100mg, Placebo
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Canoga Park, California • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes

NCT02497170
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Education of goal setting and achievement
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Somerdale, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 13, 2026, 5:51 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Customer Support Response Study

NCT01547403
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Time Restricted Eating for the Treatment of Type 2 Diabetes

NCT05225337
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Time restricted feeding (TRF), Daily calorie restriction
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

NCT01408888
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Sitagliptin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

NCT01092663
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Colesevelam HCl, Sitagliptin
Drug
Lead sponsor
KineMed
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

NCT05803421
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Interventions
Orforglipron, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
173
States / cities
Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00484198
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Rivoglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
70
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes

NCT00541606
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacist collaboration in diabetes care, Usual care
Other
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
285 participants
Timeline
2000 – 2004
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

NCT01128985
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 13, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional

Enhancing Diabetes Care by Treating Insomnia

NCT07062406
View directory record Official record
Conditions
Diabetes Type 2, Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia, Usual care for diabetes management, Usual care for treatment of insomnia
Behavioral · Other
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Zachary, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 13, 2026, 5:51 PM EDT
Terminated Not applicable Interventional Results available

Metabolic Effects of Hydroxychloroquine

NCT02026232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Hydroxychloroquine, Hydroxychloroquine Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

NCT04770532
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin Icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Buena Park, California • Encino, California • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

NCT01929863
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

NCT03985293
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
42
States / cities
Harbor City, California • Long Beach, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 13, 2026, 5:51 PM EDT
Recruiting Phase 4 Interventional

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

NCT05780905
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Interventions
Semaglutide Auto-Injector, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 13, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

NCT02682901
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
Cycloset, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 13, 2026, 5:51 PM EDT